^
    Apply
    An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (NCT05952557)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/05/2023
    Primary completion :
    03/04/2030
    Completion :
    05/06/2037
    HER-2 • ER
    |
    HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane • camizestrant (AZD9833)
    A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2) (NCT04214288)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    04/22/2020
    Primary completion :
    08/30/2022
    Completion :
    03/28/2025
    HER-2 • ER
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    fulvestrant • camizestrant (AZD9833)
    A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) (NCT05774951)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/31/2023
    Primary completion :
    04/20/2027
    Completion :
    05/29/2036
    HER-2 • ER
    |
    HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • exemestane • camizestrant (AZD9833)
    A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer (NCT04541433)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    09/29/2020
    Primary completion :
    07/29/2022
    Completion :
    12/31/2025
    HER-2 • ER
    |
    HER-2 negative
    |
    camizestrant (AZD9833)
    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (NCT04964934)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    06/30/2021
    Primary completion :
    04/25/2025
    Completion :
    11/26/2027
    HER-2 • ER
    |
    ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)
    A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) (NCT04711252)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/26/2024
    Initiation :
    01/28/2021
    Primary completion :
    08/24/2026
    Completion :
    02/01/2029
    HER-2 • ER
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • anastrozole • camizestrant (AZD9833)
    Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1) (NCT03616587)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    03/05/2024
    Initiation :
    10/11/2018
    Primary completion :
    07/10/2024
    Completion :
    09/30/2024
    HER-2 • ER
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • Truqap (capivasertib) • anastrozole • camizestrant (AZD9833)
    AZD9833 China PK Study (NCT04818632)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    10/03/2023
    Initiation :
    11/12/2021
    Primary completion :
    09/07/2023
    Completion :
    09/07/2023
    HER-2
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • everolimus • camizestrant (AZD9833)
    A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3) (NCT04588298)
    Phase 2
    AstraZeneca
    Completed
    Last update posted :
    08/03/2023
    Initiation :
    11/02/2020
    Primary completion :
    06/19/2023
    Completion :
    06/19/2023
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • ER expression • PGR expression
    |
    fulvestrant • camizestrant (AZD9833)